Saturday 17 October 2026
Export ALKS’s income statement to Excel — free account
Alkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
41.22
1.12
+2.79%
Follow ALKS
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
19.03 | 12.90 | 13.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
7 | 7 | 8 | 4 | 5 | 5 | 5 | 7 | 5 | 5 |
P/S ratio |
3.12 | 3.05 | 2.86 | 3.81 | 3.19 | 3.05 | 2.74 | 4.18 | 9.38 | 11.40 |
Altman Z-Score |
5.33 | 6.16 | 4.04 | 2.52 | 2.49 | 1.84 | 2.31 | 4.14 | 8.24 | 9.44 |
P/FCF ratio |
9.57 | 11.71 | 13.45 | 0.00 | 50.60 | 76.77 | 0.00 | 150.78 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
6.24 | 5.46 | 3.57 | 0.46 | 1.04 | 0.65 | 0.51 | 1.71 | 1.57 | 2.05 |
Beneish M-Score |
(3.29) | (2.19) | (2.10) | (2.73) | (2.32) | (2.87) | (3.31) | (3.01) | (2.77) | (2.77) |
P/Operating CF |
27.10 | 24.98 | 44.36 | 4,045.85 | 120.68 | 47.04 | 76.16 | 75.64 | 235.92 | 1,124.40 |
P/B ratio |
2.53 | 3.25 | 3.96 | 4.06 | 3.36 | 2.97 | 2.95 | 3.91 | 7.04 | 7.03 |
Price to Tangible BV |
2.66 | 3.44 | 4.26 | 4.59 | 3.96 | 3.67 | 3.81 | 5.16 | 9.92 | 10.64 |
EV/Sales |
2.42 | 2.76 | 2.57 | 3.53 | 2.98 | 2.70 | 2.52 | 3.95 | 9.21 | 11.11 |
EV/EBITDA |
12.73 | 9.56 | 8.74 | 54.63 | 19.86 | 0.00 | 0.00 | 952.62 | 0.00 | 0.00 |
EV/Operating CF |
6.87 | 9.78 | 10.65 | 186.31 | 34.44 | 33.90 | 40.87 | 43.49 | 433.53 | (129.85) |
EV/FCF |
7.43 | 10.57 | 12.09 | (227.81) | 47.35 | 68.05 | (163.99) | 142.22 | (260.41) | (77.24) |
Quick Ratio |
3.04 | 2.44 | 2.13 | 1.80 | 1.80 | 2.08 | 2.03 | 2.45 | 2.29 | 3.25 |
Current Ratio |
3.55 | 3.04 | 2.86 | 2.27 | 2.25 | 2.54 | 2.46 | 2.89 | 2.78 | 3.73 |
Net Debt/EBITDA |
(4.69) | (1.67) | (0.99) | (4.39) | (1.36) | 11.78 | 2.71 | (57.37) | 3.08 | 1.87 |
Debt/Assets |
0.00% | 0.00% | 13.61% | 14.93% | 14.61% | 14.10% | 15.35% | 15.30% | 15.66% | 16.43% |
Debt/Equity |
0.00 | 0.00 | 0.24 | 0.28 | 0.27 | 0.26 | 0.26 | 0.24 | 0.23 | 0.23 |
Asset Turnover |
0.65 | 0.74 | 0.81 | 0.56 | 0.59 | 0.55 | 0.65 | 0.60 | 0.51 | 0.42 |
Operating CF/Net income |
2.15 | 1.20 | 1.13 | (0.13) | (2.11) | (0.75) | (0.37) | (0.71) | (0.12) | 0.31 |
Capex/Depreciation |
(1.45) | (1.16) | (0.64) | (0.49) | (0.37) | (0.51) | (1.12) | (0.66) | (0.52) | (0.46) |
Interest Coverage |
20.69 | 18.63 | 17.98 | (0.47) | 8.71 | (12.98) | (12.90) | (6.42) | (12.32) | (14.01) |
| 14.72% | 27.52% | 31.67% | (14.68%) | (4.42%) | (10.30%) | (17.43%) | (11.74%) | (13.10%) | (16.52%) | |
| 10.64% | 17.51% | 17.35% | (7.94%) | (2.42%) | (5.90%) | (10.83%) | (7.69%) | (8.96%) | (11.64%) | |
ROIC |
31.75% | 36.86% | 35.95% | (0.52%) | 7.01% | (9.94%) | (13.25%) | (6.80%) | (8.80%) | (13.10%) |
Return on Tangible Assets |
15.03% | 31.17% | 29.84% | (18.50%) | (5.17%) | (10.84%) | (21.07%) | (14.61%) | (19.68%) | (24.71%) |
Average Days of Receivables |
82.61 | 90.11 | 72.96 | 94.54 | 97.39 | 96.68 | 80.14 | 97.47 | 94.38 | 93.54 |
Research and Development Expense of Revenue |
21.95% | 15.75% | 16.28% | 24.53% | 24.79% | 37.99% | 43.80% | 38.88% | 45.71% | 51.92% |
Selling, General and Administrative Expense of Revenue |
47.53% | 41.42% | 41.47% | 53.13% | 46.83% | 51.87% | 51.19% | 48.11% | 46.67% | 50.17% |
Intangible Assets out of Total Assets |
0.03 | 0.04 | 0.04 | 0.06 | 0.08 | 0.10 | 0.13 | 0.16 | 0.19 | 0.24 |
Share Based Compensation of Revenue |
6.69% | 6.20% | 6.07% | 8.48% | 7.47% | 8.68% | 8.62% | 9.63% | 9.29% | 12.66% |
Graham Net Nets |
0.27 | 0.17 | 0.12 | 0.05 | 0.04 | 0.07 | 0.08 | 0.07 | 0.03 | 0.03 |
Graham Number |
19.11 | 21.08 | 18.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
5.25% | 7.75% | 7.51% | (3.71%) | (1.29%) | (3.51%) | (6.18%) | (3.02%) | (1.87%) | (2.44%) |
Free Cash Flow Yield |
10.45% | 8.54% | 7.43% | (0.41%) | 1.98% | 1.30% | (0.56%) | 0.66% | (0.38%) | (1.26%) |
Revenue per Share |
8.96 | 9.42 | 10.01 | 6.79 | 7.29 | 6.54 | 7.46 | 7.05 | 5.89 | 4.92 |
Operating CF per Share |
3.16 | 2.66 | 2.41 | 0.13 | 0.63 | 0.52 | 0.46 | 0.64 | 0.13 | (0.42) |
Capex per Share |
(0.24) | (0.20) | (0.29) | (0.23) | (0.18) | (0.26) | (0.57) | (0.44) | (0.33) | (0.29) |
Free Cash Flow per Share |
2.92 | 2.46 | 2.13 | (0.11) | 0.45 | 0.26 | (0.11) | 0.20 | (0.21) | (0.71) |
Cash per Share |
8.01 | 4.54 | 4.65 | 3.72 | 3.33 | 4.00 | 3.41 | 3.48 | 2.83 | 3.28 |
Shareholders Equity per Share |
11.05 | 8.86 | 7.24 | 6.37 | 6.91 | 6.72 | 6.91 | 7.55 | 7.84 | 7.98 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
11.05 | 8.86 | 7.24 | 6.37 | 6.91 | 6.72 | 6.91 | 7.55 | 7.84 | 7.98 |
Free Cash Flow |
481.42 | 406.10 | 353.66 | (17.21) | 72.98 | 41.27 | (17.96) | 30.36 | (31.95) | (107.26) |
Working Capital |
1,385.72 | 950.16 | 965.29 | 632.56 | 590.88 | 672.71 | 570.86 | 643.48 | 517.72 | 578.69 |
Capital Expenditures |
(39.33) | (33.02) | (47.69) | (38.25) | (28.73) | (41.58) | (90.04) | (68.92) | (51.14) | (43.46) |
Net Current Asset Value |
1,261.46 | 824.77 | 551.97 | 210.08 | 150.27 | 228.22 | 242.01 | 329.53 | 214.43 | 273.74 |
EV/EBIT |
14.09 | 10.21 | 10.32 | 0.00 | 35.84 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.02 | 0.03 | 0.03 | 0.02 | 0.04 | 0.08 | 0.06 | 0.06 | 0.06 |
Price to Operating Income |
18.15 | 11.31 | 11.49 | 0.00 | 38.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.12 | 0.13 | 0.33 | 0.35 | 0.23 | 0.23 | 0.22 | 0.33 | 0.35 | 0.36 |
Cash ROIC |
15.34% | 18.32% | 15.60% | (0.88%) | 3.75% | 2.09% | (0.95%) | 1.53% | (1.67%) | (5.39%) |
Accounts Receivable Turnover |
4.11 | 4.34 | 5.36 | 3.70 | 3.99 | 3.90 | 4.26 | 4.16 | 4.25 | 4.30 |
Accounts Payable Turnover |
0.83 | 1.15 | 1.10 | 1.02 | 0.64 | 0.45 | 0.51 | 0.57 | 0.63 | 0.70 |
Inventory Turnover |
1.04 | 1.33 | 1.38 | 1.31 | 1.43 | 1.57 | 1.88 | 1.92 | 1.98 | 2.61 |
Average Days of Payables |
537.99 | 275.73 | 347.00 | 368.38 | 385.66 | 843.68 | 754.82 | 690.53 | 674.97 | 572.01 |
Days of Inventory on Hand |
365.31 | 272.10 | 268.89 | 303.66 | 278.08 | 257.38 | 205.99 | 186.61 | 220.01 | 174.04 |
Average Receivables |
359.28 | 358.50 | 310.22 | 300.58 | 294.17 | 266.11 | 274.65 | 262.91 | 212.35 | 173.29 |
Average Payables |
237.45 | 212.95 | 230.33 | 214.29 | 310.33 | 392.60 | 353.40 | 309.96 | 246.61 | 187.90 |
Average Inventory |
189.76 | 184.65 | 183.91 | 165.88 | 138.04 | 113.77 | 96.00 | 91.74 | 78.14 | 50.70 |
Average Assets |
2,271.28 | 2,095.90 | 2,050.10 | 1,994.23 | 1,987.11 | 1,877.57 | 1,815.21 | 1,811.12 | 1,761.83 | 1,791.08 |
Average Common Equity |
1,642.14 | 1,333.83 | 1,123.22 | 1,078.17 | 1,089.78 | 1,076.21 | 1,128.36 | 1,187.05 | 1,206.14 | 1,261.88 |
Columns are period end dates